Evercore ISI Reiterates Bullish View on Adamas Pharmaceuticals (ADMS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment
December 17, 2019 9:01 AM EST- INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) -
- Dose-response observed for both efficacy and safety -
- Safety data consistent with known safety profile of amantadine -
EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that INROADS, a 3-arm, randomized, double-blind, placebo-controlled... More
